2015 Jun 24

New citation required but conclusions have not changed

Summary of most important changes in the update:

The search for eligible studies was updated to December 2014.

No new RCTs were identified, but we did identify an erratum for one of the already included studies. Based on data provided in the erratum a descriptive result of overall survival at 5 years changed from significantly different in favour of the myeloablative therapy group to not significantly different between treatment groups, which is in accordance with our overall analysis.

For the risk of bias assessment we now used the most recent recommendations of the Childhood Cancer Group. All studies were re‐assessed using the new criteria.

2015 Jun 24

New search has been performed

The search for eligible studies was updated to December 2014.

2012 Nov 28

New citation required and conclusions have changed

Summary of most important changes in the update:

The search for eligible studies was updated to June 2012. Additional follow‐up data of one of the three already included RCTs were available. For overall survival the results changed from a significant difference in favour of myeloablative therapy into no significant difference between the treatment groups.

It should be noted that all included studies used an age of one year as the cut‐off point for pre‐treatment risk stratification. Recently the age cut‐off for high risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate risk disease have been included in the high risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned.

2012 Nov 28

New search has been performed

The search for eligible studies was updated to June 2012.

2010 Dec 07

Amended

Contact details updated.

2008 Nov 04

Amended

amended: converted to new review format